Thomasville National Bank Has $819,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Thomasville National Bank lowered its stake in shares of Danaher Co. (NYSE:DHR) by 3.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,280 shares of the conglomerate’s stock after selling 119 shares during the period. Thomasville National Bank’s holdings in Danaher were worth $819,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares during the last quarter. Capital International Investors raised its position in Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares during the last quarter. Northern Trust Corp raised its position in Danaher by 1.7% in the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after buying an additional 134,905 shares during the last quarter. Finally, Norges Bank acquired a new stake in Danaher in the 4th quarter valued at approximately $1,752,382,000. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. In the last quarter, insiders sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $248.70 on Friday. The stock has a fifty day moving average price of $254.16 and a 200-day moving average price of $245.03. The company has a market cap of $184.21 billion, a price-to-earnings ratio of 42.15, a PEG ratio of 3.94 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the previous year, the firm earned $2.36 EPS. Danaher’s revenue was down 2.6% on a year-over-year basis. As a group, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. Jefferies Financial Group initiated coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Citigroup lifted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Robert W. Baird lifted their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, TD Cowen boosted their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $269.29.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.